GO:0034379 very-low-density lipoprotein particle assembly: Hepatic Lipoprotein Biogenesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034379 describes the non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein (VLDL) particle.
• VLDL assembly is a two-step process in which apolipoprotein B (APOB) is co-translationally lipidated in the endoplasmic reticulum, followed by a second bulk lipidation step to form the mature secretion-competent particle.
• The process requires a village of factors including APOB, MTTP, SAR1B, and COPII machinery, and its failure causes hepatic steatosis and dyslipidaemia.
• VLDL assembly is regulated by intracellular tPA-PAI-1 interaction and by CREBH processing, linking it to metabolic and inflammatory signalling.
• Dysregulated VLDL assembly is central to diabetic dyslipidaemia, non-alcoholic fatty liver disease, and cardiovascular risk.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of VLDL assembly genes in hepatocyte systems.
Description
Very-low-density lipoprotein (VLDL) particle assembly (GO:0034379) is the biological process by which the liver packages apolipoproteins and lipids into a secreted lipoprotein particle. This process is essential for the transport of endogenously synthesised triglycerides and cholesterol from the liver to peripheral tissues, and it represents a central node in systemic lipid homeostasis. Defects in VLDL assembly are directly linked to hepatic steatosis, hypertriglyceridaemia, and diabetic dyslipidaemia, making this GO term a high-value target for metabolic disease research. At the molecular level, VLDL assembly is not a single event but a coordinated, multi-step pathway that begins with the translation of APOB and its co-translational lipidation by microsomal triglyceride transfer protein (MTTP) in the endoplasmic reticulum. A second, bulk lipidation step then generates the mature VLDL particle, which is exported via the secretory pathway. Recent work has revealed that this process is modulated by intracellular signalling complexes, including the tPA-PAI-1 interaction, and is coupled to the processing of transcription factors such as CREBH. For researchers, GO:0034379 provides a structured framework for interrogating hepatic lipid metabolism, lipoprotein secretion, and the molecular basis of dyslipidaemia. Understanding which genes are causally required for VLDL assembly, and how mutations in those genes alter particle formation, is a prerequisite for developing targeted therapeutics.
very-low-density lipoprotein particle assembly At A Glance
| GO ID | GO:0034379 |
|---|---|
| GO term | very-low-density lipoprotein particle assembly |
| Ontology | biological_process |
| Synonym | VLDL assembly |
| Definition | The non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle. |
| Major function | Packaging of hepatic triglycerides, cholesterol, and apolipoproteins into a secreted lipoprotein particle for systemic lipid transport. |
| Cellular location | Endoplasmic reticulum and Golgi apparatus of hepatocytes. |
| Key molecular players | APOB, MTTP, SAR1B, COPII components, and accessory factors such as CREBH and tPA-PAI-1. |
| Associated disease | Hepatic steatosis, hypertriglyceridaemia, diabetic dyslipidaemia, and cardiovascular disease. |
What Is GO:0034379?
GO:0034379 (very-low-density lipoprotein particle assembly) is defined as the non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle. In practical terms, it encompasses the molecular events that convert newly synthesised apolipoprotein B and associated lipids into a secretion-competent VLDL particle, including the initial co-translational lipidation step and the subsequent bulk lipid loading step.
Why Is very-low-density lipoprotein particle assembly Important in Cell Biology?
VLDL assembly is the rate-limiting step for hepatic triglyceride export, and its dysregulation is a direct cause of fatty liver and hypertriglyceridaemia. Because VLDL particles are the primary carriers of endogenous triglycerides and cholesterol, the assembly process sits at the intersection of hepatic lipid metabolism, systemic energy homeostasis, and cardiovascular risk. Consequently, genes that control VLDL assembly are high-priority targets for both mechanistic studies and therapeutic development in metabolic disease.
• VLDL assembly is required for the export of hepatic triglycerides, preventing lipid accumulation in the liver.
• Failure of VLDL assembly causes hepatic steatosis and contributes to non-alcoholic fatty liver disease.
• Overproduction of VLDL is a hallmark of diabetic dyslipidaemia and increases cardiovascular risk.
• APOB, the structural scaffold of VLDL, is a validated biomarker and therapeutic target for lipid disorders.
• MTTP is essential for the co-translational lipidation step, and its inhibition is a pharmacological strategy for lowering atherogenic lipoproteins.
• SAR1B and COPII components link VLDL assembly to endoplasmic reticulum export and secretory cargo handling.
• The tPA-PAI-1 interaction modulates VLDL assembly, connecting coagulation and lipid metabolism.
• CREBH processing is functionally coupled to VLDL assembly, linking the acute-phase response to lipoprotein production.
• VLDL assembly is a model system for studying two-step protein lipidation and ER-to-Golgi transport.
• CRISPR-based models of VLDL assembly genes enable causal testing of lipid metabolism hypotheses.
What Happens During very-low-density lipoprotein particle assembly?
Step 1: APOB translation and co-translational lipidation
In simple terms: The cell first builds the protein backbone of VLDL and attaches some fat to it while the protein is still being made.
VLDL assembly begins with the translation of APOB in the endoplasmic reticulum (ER) of hepatocytes. During translation, MTTP transfers lipids to the nascent APOB polypeptide, a step known as co-translational lipidation. This initial lipidation is required for APOB to fold correctly and to avoid degradation, and it produces a partially lipidated APOB intermediate.
Step 2: Bulk lipidation and particle maturation
In simple terms: The partially built particle then receives a large load of fat to become a full, mature VLDL particle.
The second step of VLDL assembly involves the bulk addition of triglycerides and other lipids to the partially lipidated APOB, forming the mature VLDL particle. This step is distinct from the co-translational lipidation and is thought to occur in the ER lumen or a post-ER compartment. The resulting particle is a spherical lipoprotein with a neutral lipid core and a surface monolayer of phospholipids and apolipoproteins.
Step 3: ER-to-Golgi transport and secretion
In simple terms: Once assembled, the VLDL particle is packaged into a transport vesicle and sent out of the liver cell.
After assembly, VLDL particles are transported from the ER to the Golgi apparatus via COPII-coated vesicles, a process that requires SAR1B and other secretory machinery components. The particles are then secreted into the circulation, where they deliver triglycerides to peripheral tissues. Defects in this transport step can cause VLDL retention in the ER and trigger ER stress.
Step 4: Regulation by intracellular signalling and transcription factors
In simple terms: The assembly line is controlled by signals inside the cell that tell it when to speed up or slow down.
VLDL assembly is dynamically regulated by intracellular signalling. The interaction between tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) within hepatocytes determines VLDL assembly efficiency. In addition, VLDL assembly is required for the processing of cAMP-responsive element-binding protein H (CREBH), which in turn regulates hepatic apolipoprotein A-IV expression. These findings place VLDL assembly within a broader network of metabolic and inflammatory signalling.
Key Genes Involved in GO:0034379 very-low-density lipoprotein particle assembly
The following genes and proteins are experimentally established participants in or regulators of very-low-density lipoprotein particle assembly (GO:0034379).
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOB | Structural scaffold apolipoprotein of VLDL; required for particle assembly and secretion | Core target for studies of lipoprotein biogenesis and dyslipidaemia |
| MTTP | Transfers lipids to nascent APOB during co-translational lipidation | Essential factor for VLDL assembly; pharmacological target |
| SAR1B | COPII GTPase required for ER-to-Golgi transport of VLDL particles | Links VLDL assembly to secretory pathway function |
| CREBH | Transcription factor processed in a VLDL-assembly-dependent manner | Connects VLDL assembly to hepatic acute-phase and lipid gene expression |
| PLAT (tPA) | Interacts with PAI-1 to regulate VLDL assembly in hepatocytes | Provides a link between coagulation and lipid metabolism |
| SERPINE1 (PAI-1) | Intracellular binding partner of tPA that determines VLDL assembly | Modulates VLDL assembly efficiency |
| APOA4 | Hepatic apolipoprotein whose expression depends on VLDL assembly and CREBH processing | Downstream readout of VLDL assembly status |
| APOA5 | Modulates VLDL secretion and triglyceride metabolism | Genetic variant associated with hypertriglyceridaemia |
| APOC3 | Inhibits lipoprotein lipase and modulates VLDL metabolism | Therapeutic target for triglyceride lowering |
| LDLR | Clears VLDL remnants and LDL from circulation | Central to cholesterol homeostasis and cardiovascular risk |
| LPL | Hydrolyses triglycerides in VLDL particles in peripheral tissues | Determines VLDL clearance rate |
| INSIG1 | Regulates SREBP processing and hepatic lipogenesis, indirectly affecting VLDL assembly | Links lipogenesis to VLDL production |
| SREBF1 | Transcription factor controlling lipogenic gene expression for VLDL lipid supply | Upstream regulator of substrate availability |
| SREBF2 | Transcription factor controlling cholesterol synthesis and LDLR expression | Modulates cholesterol availability for VLDL |
| DGAT1 | Catalyses triglyceride synthesis for VLDL lipid core | Enzyme supplying lipid substrate for VLDL assembly |
| DGAT2 | Catalyses triglyceride synthesis and associates with VLDL assembly | Potential therapeutic target for hepatic steatosis |
| PCSK9 | Regulates LDLR degradation and influences plasma lipid levels | Clinically validated lipid-lowering target |
How Is very-low-density lipoprotein particle assembly Regulated?
VLDL assembly is regulated at multiple levels. Transcriptionally, SREBP-1c and SREBP-2 control the expression of lipogenic and cholesterol biosynthetic genes that supply lipids for particle assembly. Post-translationally, the intracellular interaction between tPA and PAI-1 determines the efficiency of VLDL assembly in hepatocytes. In addition, VLDL assembly is functionally coupled to the processing of CREBH, a transcription factor that regulates hepatic apolipoprotein A-IV expression, thereby linking lipoprotein assembly to the acute-phase response. These regulatory layers ensure that VLDL production is matched to hepatic lipid availability and systemic metabolic demand.
very-low-density lipoprotein particle assembly and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOB | Familial hypobetalipoproteinaemia; hepatic steatosis; dyslipidaemia | APOB knockout hepatocyte cell line; knock-in of patient mutations |
| MTTP | Abetalipoproteinaemia; hepatic steatosis | MTTP knockout HepG2 cells; point-mutation rescue |
| SAR1B | Chylomicron retention disease; defective lipoprotein secretion | SAR1B knockout hepatocytes; tagged knock-in for trafficking studies |
| CREBH | Hepatic acute-phase response; apolipoprotein A-IV regulation | CREBH knockout and overexpression models in hepatocytes |
| SERPINE1 (PAI-1) | Metabolic syndrome; thrombosis; VLDL assembly regulation | PAI-1 knockout and point-mutation hepatocyte models |
Diabetic dyslipidaemia and hypertriglyceridaemia
Overproduction of VLDL is a central feature of diabetic dyslipidaemia, contributing to elevated plasma triglycerides and increased cardiovascular risk. Insulin resistance increases hepatic VLDL secretion, and the resulting hypertriglyceridaemia is a hallmark of type 2 diabetes. Genes controlling VLDL assembly, including APOB and MTTP, are therefore directly relevant to the pathophysiology of diabetic lipid disorders.
Hepatic steatosis and non-alcoholic fatty liver disease
When VLDL assembly or secretion is impaired, triglycerides accumulate in hepatocytes, causing hepatic steatosis. Defects in APOB, MTTP, or SAR1B function lead to reduced VLDL secretion and lipid retention in the liver. This mechanistic link makes VLDL assembly genes attractive targets for understanding and treating non-alcoholic fatty liver disease.
Cardiovascular disease and atherosclerosis
VLDL particles and their remnants are atherogenic, and elevated VLDL production increases cardiovascular risk. APOB-containing lipoproteins are the primary drivers of atherosclerotic plaque formation, and LDLR-mediated clearance of VLDL remnants is a key determinant of plasma cholesterol levels. Therapeutic strategies that lower VLDL production or enhance clearance are therefore central to cardiovascular prevention.
From very-low-density lipoprotein particle assembly-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is APOB strictly required for VLDL assembly? | APOB knockout hepatocyte cell line (e.g., HepG2 or primary hepatocytes) |
| Does a patient-derived MTTP mutation impair co-translational lipidation? | MTTP point-mutation knock-in via CRISPR |
| Where does SAR1B act in VLDL transport? | SAR1B tagged knock-in for live-cell imaging |
| Does overexpression of CREBH increase VLDL assembly? | CREBH overexpression in hepatocytes |
| Does the tPA-PAI-1 interaction quantitatively control VLDL assembly? | PAI-1 point-mutation and knockout models |
| Can a candidate gene rescue VLDL secretion in a knockout background? | CRISPR knockout plus overexpression rescue |
How to Study the very-low-density lipoprotein particle assembly Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Metabolic labelling with 35S-methionine | Newly synthesised APOB and its lipidation state | Quantifying VLDL assembly and secretion rates |
| Density-gradient ultracentrifugation | Distribution of lipoproteins by density | Isolating VLDL particles for compositional analysis |
| CRISPR knockout | Loss-of-function effect on VLDL assembly | Testing causal requirement of candidate genes |
| CRISPR point-mutation knock-in | Effect of specific patient variants | Modelling familial hypobetalipoproteinaemia mutations |
| Live-cell fluorescence imaging | Subcellular localisation and trafficking of assembly factors | Visualising ER-to-Golgi VLDL transport |
| RNA sequencing | Transcriptional changes downstream of VLDL assembly perturbation | Identifying CREBH-dependent gene networks |
| Immunoprecipitation of APOB | APOB protein levels and interactions | Assessing APOB stability and lipidation |
| Triglyceride secretion assay | Rate of triglyceride export from hepatocytes | Functional readout of VLDL assembly capacity |
Lipoprotein secretion assays
VLDL assembly and secretion are commonly measured by metabolic labelling of hepatocytes with radioactive or stable-isotope-labelled amino acids, followed by immunoprecipitation of APOB and density-gradient ultracentrifugation to separate VLDL from denser lipoproteins. These assays directly quantify the amount of newly synthesised APOB that is lipidated and secreted.
CRISPR-based genetic perturbation
CRISPR knockout, point-mutation knock-in, and overexpression models allow causal testing of genes implicated in VLDL assembly. For example, knockout of MTTP or SAR1B in hepatocyte lines followed by APOB secretion assays can define the step at which each factor acts. Point mutations can be introduced to model patient variants and assess their impact on particle assembly.
Imaging and organelle trafficking
Fluorescence microscopy of tagged APOB, SAR1B, or COPII components enables visualisation of VLDL assembly intermediates and their movement from the ER to the Golgi. Live-cell imaging with tagged knock-in alleles provides spatial and temporal resolution of the assembly process.
Transcriptomic and proteomic profiling
RNA sequencing and quantitative proteomics of hepatocytes with perturbed VLDL assembly genes can identify downstream transcriptional and proteomic changes, including CREBH-dependent apolipoprotein expression. These approaches place VLDL assembly within broader metabolic gene networks.
How CRISPR Can Be Used to Study GO:0034379 very-low-density lipoprotein particle assembly
Knockout
CRISPR knockout of genes such as APOB, MTTP, or SAR1B in hepatocyte cell lines abolishes or severely impairs VLDL assembly, providing definitive loss-of-function evidence for their requirement in the process. Knockout models are also used to establish a clean background for rescue experiments with wild-type or mutant alleles.
Point Mutation
CRISPR point-mutation knock-in allows precise modelling of patient-derived variants in VLDL assembly genes, such as APOB or MTTP mutations associated with hypobetalipoproteinaemia. These models distinguish between variants that impair co-translational lipidation and those that affect later assembly steps.
Knock-in
Tagged knock-in of genes such as SAR1B or APOB enables live-cell imaging and biochemical tracking of VLDL assembly intermediates without overexpression artefacts. Knock-in of reporter or affinity tags supports proteomic and trafficking studies of the assembly machinery.
Overexpression
CRISPR-mediated overexpression or cDNA-based overexpression of regulators such as CREBH or tPA-PAI-1 pathway components can enhance or perturb VLDL assembly, allowing gain-of-function analysis. Overexpression rescue in a knockout background is a standard approach to confirm that a specific gene is sufficient to restore VLDL assembly.
How EDITGENE Supports very-low-density lipoprotein particle assembly Research
Researchers studying very-low-density lipoprotein particle assembly-related genes often need to determine whether a candidate gene is causally involved in particle formation, how specific patient variants alter assembly efficiency, and which downstream pathways are affected. Addressing these questions requires precise, reproducible genetic models in relevant hepatocyte systems, coupled with functional assays that directly measure VLDL assembly and secretion.
Contact EDITGENE today to design your custom CRISPR model for very-low-density lipoprotein particle assembly research.
Frequently Asked Questions About very-low-density lipoprotein particle assembly
What is very-low-density lipoprotein particle assembly?
Very-low-density lipoprotein particle assembly (GO:0034379) is the non-covalent aggregation and arrangement of proteins and lipids in the liver to form a VLDL particle, a process essential for hepatic triglyceride export.
What genes are involved in very-low-density lipoprotein particle assembly?
Key genes include APOB, which forms the structural scaffold, MTTP, which lipidates APOB, SAR1B, which mediates ER-to-Golgi transport, and CREBH, which is processed in a VLDL-assembly-dependent manner.
What is the GO ID for VLDL assembly?
The Gene Ontology ID for VLDL assembly is GO:0034379, classified under biological_process.
Why is VLDL assembly important for liver health?
VLDL assembly is the primary route for exporting triglycerides from the liver; when it fails, triglycerides accumulate and cause hepatic steatosis.
How is VLDL assembly regulated?
VLDL assembly is regulated by transcription factors such as SREBP-1c, by the intracellular tPA-PAI-1 interaction, and by CREBH processing.
What diseases are linked to defective VLDL assembly?
Defective VLDL assembly is linked to hepatic steatosis, abetalipoproteinaemia, familial hypobetalipoproteinaemia, diabetic dyslipidaemia, and cardiovascular disease.
What is the two-step model of VLDL assembly?
The two-step model proposes that APOB is first lipidated co-translationally by MTTP, and then receives a bulk lipid load to form the mature VLDL particle.
Which experimental methods are used to study VLDL assembly?
Common methods include metabolic labelling of APOB, density-gradient ultracentrifugation, CRISPR knockout and knock-in, live-cell imaging, and RNA sequencing.
Can CRISPR be used to model VLDL assembly disorders?
Yes, CRISPR knockout, point-mutation knock-in, and overexpression models in hepatocytes allow causal testing of VLDL assembly genes and patient variants.
What is the role of MTTP in VLDL assembly?
MTTP transfers lipids to nascent APOB during co-translational lipidation, a required step for VLDL particle formation.
Conclusion
Very-low-density lipoprotein particle assembly (GO:0034379) is a multi-step, genetically tractable process that governs hepatic triglyceride export and systemic lipid homeostasis. Its core machinery, including APOB, MTTP, and SAR1B, is well defined, and its regulation by tPA-PAI-1 and CREBH links it to metabolic and inflammatory signalling. Dysregulation of VLDL assembly underlies major human diseases, including hepatic steatosis, diabetic dyslipidaemia, and cardiovascular disease. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide the causal resolution needed to move from gene association to mechanism in VLDL assembly research. Combined with functional secretion assays and omics profiling, these models offer a robust path toward identifying and validating therapeutic targets in lipid disorders.
References
- 1. van Zwol W et al.. 2024. VLDL Biogenesis and Secretion: It Takes a Village.. Circ Res 134(2):226-244 PMID: 38236950
- 2. Shelness GS et al.. 2001. Very-low-density lipoprotein assembly and secretion.. Curr Opin Lipidol 12(2):151-7 PMID: 11264986
- 3. Adiels M et al.. 2006. Diabetic dyslipidaemia.. Curr Opin Lipidol 17(3):238-46 PMID: 16680028
- 4. Devaraj S et al.. 2026. Biochemistry, Apolipoprotein B.. PMID: 30844166
- 5. Rustaeus S et al.. 1999. Assembly of very low density lipoprotein: a two-step process of apolipoprotein B core lipidation.. J Nutr 129(2S Suppl):463S-466S PMID: 10064310
- 6. Dai W et al.. 2023. Intracellular tPA-PAI-1 interaction determines VLDL assembly in hepatocytes.. Science 381(6661):eadh5207 PMID: 37651538
- 7. Cheng D et al.. 2016. Very Low Density Lipoprotein Assembly Is Required for cAMP-responsive Element-binding Protein H Processing and Hepatic Apolipoprotein A-IV Expression.. J Biol Chem 291(45):23793-23803 PMID: 27655915
